PPARA and diabetic kidney disease: Several metabolic experimental studies, including murine studies employing a high-fat-diet-induced glomerular injury model or a diabetic nephropathy model, have also demonstrated the beneficial properties of the PPARα agonist fibrates in reducing glomerular lesions [25–28].